Merck turns to cardiovascular pipeline for its post-Keytruda future
For some years industry observers have been asking what Merck & Co can do to reduce its reliance on blockbuster cancer immunotherapy Keytruda. Now, it […]
For some years industry observers have been asking what Merck & Co can do to reduce its reliance on blockbuster cancer immunotherapy Keytruda. Now, it […]
Merck is looking for products that diversify its portfolio beyond reliance on cancer drug Keytruda, and it sees a potential blockbuster cardiovascular drug from Acceleron […]
Shots: The BREEZE study evaluates Tyvaso DPI vs nebulized Tyvaso in 51 patients with PAH who were transitioned from Tyvaso to Tyvaso DPI at a […]
Shots: The P-III GRIPHON & P-IIIb TRITON trials evaluate Uptravi vs control group in 404 & 245 patients with PAH, respectively The results from a […]
Shots: The approval is based on P-III UPTRAVI IV study evaluating the safety, tolerability, and PK of temporarily switching Uptravi (PO) to Uptravi (IV) in […]
Shots: The P-I study will evaluate the PK and safety profile of R-107 vs PBO in patients with PAH. Earlier, Claritas licensed R-107 from Salzman […]
Shots: The P-II PULSAR trial involves assessing Sotatercept (0.3 mg/kg or 0.3 mg/kg, SC, q3w) vs PBO in 106 patients in a ratio (3:3:4) with […]
The FDA decision for Tyvaso as a treatment for pulmonary arterial hypertension in patients who have interstitial lung disease is the second approval for the […]
Shots: The NDA submission is based on P-III UPTRAVI IV study he safety and tolerability of 20 patients with PAH temporarily switching from oral UPTRAVI […]
Copyright © 2024 | WordPress Theme by MH Themes